incretin semaglutide & Hormone Receptor Agonists | Sterile Dual and Triple Incretin-Based Co-agonists:

Due to its stability and broad biological relevance, BPC-157 is commonly utilized in in-vitro and biochemical studies focused on tissue modeling, angiogenic signaling, and peptide-regulated cellular responses

As of April 2026, retatrutide is investigational

Whats happening: Hims & Hers Health (NYSE: HIMS) has launched a new meal subscription plan focused on providing deeper nutritional support for individuals looking to lose weight as well as for individuals who have already been prescribed weight loss drugs Why it matters: Hims & Hers Health has been seeing an explosion in user growth recently, which has largely been fuelled by providing streamlined access to generic versions of GLP-1 weight loss drugs through their telemedicine platform Going deeper: The new meal subscription plan being rolled out by Hims & Hers Health is aiming to ensure that individuals who are taking GLP-1 drugs are still consuming nutrient dense foods despite a potentially significant decrease in appetite which is a common side effect caused by taking weight loss drugs Hims & Hers Healths offers a variety of different medications and pharmaceuticals including treatments for anxiety, skin care and even sex however their weight loss drug subscription plans have become the fastest growing aspect of their business The intrigue: Hims & Hers has also rolled out name brand GLP-1s such as Novo Nordisks (NYSE: NVO) Ozempic and Wegovy but has struggled to find consistent supply through their pharmaceutical wholesale partner due to the enormous demand for weight loss drugs in the United States of America

However, it can be legally sold and purchased as a research chemical for legitimate research purposes

Babizhayev et al

The executives on the other side of that table have nothing but skin in the game